BMO Capital Markets Increases Eli Lilly and Company (NYSE:LLY) Price Target to $1,101.00

Eli Lilly and Company (NYSE:LLY) had its price target upped by research analysts at BMO Capital Markets from $1,001.00 to $1,101.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. BMO Capital Markets’ price target suggests a potential upside of 23.47% from the company’s current price.

A number of other equities analysts have also recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday, August 5th. Argus increased their target price on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. Barclays lifted their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Morgan Stanley reissued an “overweight” rating and set a $1,023.00 price objective on shares of Eli Lilly and Company in a research note on Friday, July 5th. Finally, Berenberg Bank lifted their target price on shares of Eli Lilly and Company from $850.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Three analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $916.53.

Eli Lilly and Company Price Performance

NYSE LLY traded up $46.37 on Friday, reaching $891.68. 6,587,628 shares of the company’s stock traded hands, compared to its average volume of 3,089,428. The stock has a market cap of $847.46 billion, a PE ratio of 131.32, a P/E/G ratio of 1.81 and a beta of 0.41. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. Eli Lilly and Company has a 12 month low of $516.57 and a 12 month high of $966.10. The stock has a 50-day simple moving average of $871.07 and a 200 day simple moving average of $795.47.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the transaction, the chief accounting officer now directly owns 7,130 shares in the company, valued at $5,842,821.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, major shareholder Lilly Endowment Inc sold 2,052 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the completion of the sale, the insider now owns 98,554,195 shares of the company’s stock, valued at $79,730,343,755. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the transaction, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,214,704 shares of company stock worth $1,066,841,316. 0.13% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Eli Lilly and Company

A number of large investors have recently added to or reduced their stakes in the stock. Lipe & Dalton purchased a new stake in Eli Lilly and Company during the fourth quarter valued at approximately $26,000. Tidemark LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter worth $29,000. Core Wealth Advisors Inc. increased its stake in shares of Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares in the last quarter. Lynx Investment Advisory bought a new position in Eli Lilly and Company in the 2nd quarter worth $32,000. Finally, LGT Financial Advisors LLC purchased a new position in Eli Lilly and Company during the second quarter valued at $36,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.